JNJ-2113

AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested.

The FDA has granted Fast Track Designation for Johnson & Johnson's nipocalimab to treat Sjögren's disease, following its earlier Breakthrough Therapy Designation, potentially accelerating development for this autoimmune condition.

Protagonist Therapeutics secured a significant $165 million milestone payment for icotrokinra in Q4 2024, strengthening their financial position with total cash reserves of $559.2 million.

Johnson & Johnson has initiated a New Drug Application (NDA) submission to the FDA for TAR-200.

Rusfertide significantly reduced the need for phlebotomies in polycythemia vera (PV) patients, with 77% achieving clinical response compared to 33% on placebo.